0.02
-0.0001(-0.50%)
Currency In USD
Address
3525 Del Mar Heights Road
San Diego, CA 92130
United States of America
Phone
858 800 2543
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
August 13, 2021
| Name | Title | Pay | Year Born |
| Mr. Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman | 397,600 | 1959 |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | 27,040 | 1952 |
| Mr. David F. Hale | Co-Founder & Lead Independent Director | 73,000 | 1949 |
| Ms. Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President & Chief Financial Officer | 438,876 | 1979 |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President & Chief Development Officer | 466,932 | 1966 |
| Mr. Sean Proehl | Associate General Counsel | 0 | N/A |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
